Obsidian Therapeutics Announces Expansion of Leadership Team – Yahoo Finance

Additions support Obsidian's active program development, operational build-out and ongoing regulatory discussions

CAMBRIDGE, Mass., Nov. 12, 2019 /PRNewswire/-- Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of three key members of the Company's development team: Shyam Subramanian, Ph.D., Vice President and Head of Technical Operations; Parnian Zia-Amirhosseini, Ph.D., Vice President and Head of Regulatory Affairs and Quality Assurance; and Melanie Call, Vice President and Head of Program Development.

Obsidian Therapeutics Announces Expansion of Leadership Team

Dr. Subramanian will lead all aspects of CMC, including process development, analytical development and manufacturing for Obsidian's product portfolio. Dr. Zia-Amirhosseini will lead Obsidian's regulatory efforts and will oversee all product quality initiatives. Ms. Call will lead program management across all internal and external programs at the company, including shepherding Obsidian's lead candidate through IND-enabling studies in 2020.

"Obsidian is rapidly building our development team as we prepare our lead program for first-in-human studies," said Catherine Stehman-Breen, M.D., Obsidian's Chief Development Officer. "The appointments of Shyam, Parnian and Melanie, all exceptionally talented and experienced individuals, signal our focus on moving these important and novel therapeutics into patients. I am thrilled with our momentum and ability to attract leading talent in our industry."

Dr. Subramanian brings to Obsidian over 20 years of post-discovery through commercialization product development experience in biologics, including products in the cell and gene therapy space. Prior to joining Obsidian, Dr. Subramanian was the Head of Cell Therapy Development & Manufacturing at Casebia Therapeutics, leading the CMC development of several novel CRISPR-edited T-cell therapy product candidates for autoimmune diseases. Prior to Casebia, Dr. Subramanian spent 20 years in biopharmaMerck, Chiron, Teva and Johnson & Johnsonwith responsibility for early- and late-stage process development, technology transfer and manufacturing support for viral and bacterial vaccines, antibodies, and gene therapy vectors. Dr. Subramanian holds a Ph.D. in Chemical and Biomolecular Engineering from the University of Pennsylvania.

Dr. Zia-Amirhosseini brings to Obsidian 25 years of experience in drug development. She has led regulatory activities for both early and late-stage development programs in multiple therapeutic areas including oncology. Prior to joining Obsidian, Dr. Zia-Amirhosseini was the Executive Director of Regulatory Affairs at Sarepta Therapeutics and the Executive Director of Regulatory Affairs and Quality Assurance at Ambrx. Prior to Ambrx, she worked at Amgen for 14 years, in roles of increasing responsibility, concluding her time as the Global Regulatory Leader for oncology, bone and inflammation projects. She started her career as a reviewer at the Office of Clinical Pharmacology and Biopharmaceutics at FDA. Dr. Zia-Amirhosseini holds a Ph.D. from the University of California, San Francisco, in Pharmaceutical Chemistry.

Ms. Call brings to Obsidian over 25 years of product development, program management and strategic planning experience across multiple therapeutic areas in cell therapy, protein and small molecule therapeutics, and drug delivery. Prior to joining Obsidian, Ms. Call led the Accelerating Center at the Cell and Gene Therapy Center at IQVIA. Prior to IQVIA, she was Vice President, Strategic Planning and Operations at ImmunoCellular Therapeutics, focused on the development of cell therapies in oncology. Previously, Ms. Call worked at Amgen for more than 20 years in product development and R&D project management. While at Amgen, she provided operational leadership for more than 20 cross-functional product development teams, creating and executing global strategic plans that included integrated project planning, product profile development and risk management. Ms. Call holds an M.B.A. from Washington State University and a B.A. in Zoology from the University of Idaho.

Story continues

About Obsidian TherapeuticsObsidian Therapeutics is a biotechnology company pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian's proprietary cytoDRiVE technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression. The cytoDRiVE platform can be applied to design controllable intracellular, membrane and secreted proteins for cell and gene therapies as well as other applications. The Company's initial applications focus on developing novel cell therapies for the treatment of cancer. Obsidian is headquartered in Cambridge, Mass. For more information, please visit http://www.obsidiantx.com.

Media Contact:Maggie BellerRusso Partners, LLCMaggie.beller@russopartnersllc.com646-942-5631

View original content to download multimedia:http://www.prnewswire.com/news-releases/obsidian-therapeutics-announces-expansion-of-leadership-team-300956130.html

Excerpt from:
Obsidian Therapeutics Announces Expansion of Leadership Team - Yahoo Finance

Lytix Biopharma announces a clinical collaboration agreement with Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) – BioSpace

Lytix Biopharma AS, a Norwegian clinical stage immunoncology company, today announces a clinical collaboration with the US-based company Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, to evaluate Lytix`s first-in-class oncolytic peptide, LTX-315, in combination with Iovance`s autologous ready to infuse T cell therapy.

Lytix Biopharma is focused on the development of oncolytic molecules based on pioneering research in host defense peptides. The company`s lead compound, LTX-315, is administrated intra-tumorally and works by inducing lysis of intracellular organelles of tumor cells thereby unleashing a broad spectra of tumor antigens. Clinical trials have demonstrated an increase in CD8+ TILs in the majority of evaluated patients with solid tumors resulting in size reduction of distant non-treated lesions.

Iovance Biotherapeutics intends to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patients own immune cells to attack cancer. TIL cells are extracted from a patients own tumor tissue, expanded through a proprietary process, and infused back into the patient. After infusion TILs reach tumor tissue where they attack tumor cells.

The collaboration is a non-exclusive collaboration where both parties will maintain ownership of their own assets.

ystein Rekdal, CEO of Lytix Biopharma, said: We are very excited about the collaboration with Iovance, and the combination of our technologies can be a potential new approach to T cell therapy for cancers. This agreement affirms that we remain committed to the further development of LTX-315 as a single agent and in combination with other therapies.

For more information contact:

ystein Rekdal, CEO, e-mail: oystein.rekdal@lytixbiopharma.com

Follow this link:
Lytix Biopharma announces a clinical collaboration agreement with Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) - BioSpace

Unum Therapeutics Reports Third Quarter 2019 Financial Results – Yahoo Finance

- Progress towards focusing on solid tumors remains on track with enrollment and early safety updates from Phase 1 trial of ACTR707 in HER2+ cancers expected by the end of this year-

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today reported financial results and corporate updates for the third quarter ended September 30, 2019, and provided recent activities.

Our recently announced strategic focus towards addressing the challenge of treating solid tumor cancers is well underway with ACTR707, BOXR1030, and our BOXR platform that is designed to discover new product candidates aimed at improving the function of T cell therapies in the solid tumor microenvironment, said Chuck Wilson Ph.D., President and Chief Executive Officer of Unum. BOXR1030, which co-expresses the GOT2 transgene and is designed to improve T cell metabolism and reduce T cell exhaustion, generated complete tumor regressions under metabolically challenging conditions in preclinical studies as presented at the SITC meeting. For ACTR707, our Phase 1 trial is progressing nicely and we remain on track to report enrollment and early safety updates from patients treated in the first dose cohort by the end of this year.

Recent Program and Corporate Highlights

Separately, Unum and its partner, Seattle Genetics, Inc., have suspended further dose-escalation of the ATTCK-17-01 Phase 1 trial of ACTR087 with SEA-BCMA in multiple myeloma pending a further review of this program. Two additional cohorts of patients have been treated in the Phase 1 trial in 2019, escalating doses of the SEA-BCMA antibody to 2.0 mg/kg and of the ACTR087+ T cells to 50M. No dose-limiting toxicities (DLTs) following ACTR087 administration were reported and no severe adverse events of cytokine release syndrome (CRS) or neurologic events have been observed to date.

Third Quarter 2019 Financial Results

About Unum TherapeuticsUnum Therapeutics is a clinical-stage biopharmaceutical company focused on developing curative cell therapies to treat a broad range of cancer patients. Unums novel proprietary technologies include Antibody-Coupled T cell Receptor (ACTR), an autologous engineered T-cell therapy that combines the cell-killing ability of T cells and the tumor-targeting ability of co-administered antibodies to exert potent antitumor immune responses, and Bolt-On Chimeric Receptor (BOXR), designed to improve the functionality of engineered T cells by incorporating a bolt-on transgene to overcome resistance of the solid tumor microenvironment to T cell attack. Unum has multiple programs in Phase 1 clinical and preclinical testing, including; ACTR707 used in combination with trastuzumab in adult patients with HER2+ advanced cancer and used in combination with rituximab in adult patients with r/r NHL; and BOXR1030 expressing the GOT2 transgene and targeting GPC3+ solid tumor cancers. The Company is headquartered in Cambridge, MA.

Follow Unum Therapeutics on social media: @UnumRx, and LinkedIn.

Forward looking Statements

This press release contains forward-looking statements including, without limitation, statements regarding our future expectations, plans and prospects, including projections regarding future revenues and financial performance, our long-term growth, enrollment and results for our preclinical and clinical activities, the development of our product candidates, including the ACTR product candidates and the BOXR platform and product candidates, and the anticipated timing and success of any of our preclinical studies, clinical trials and regulatory filings, as well as other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, as amended. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to the accuracy of our estimates regarding expenses, future revenues, capital requirements, and the need for additional financing, the success, cost and timing of our product development activities and clinical trials, our ability to obtain and maintain regulatory approval for our product candidates, and the other risks and uncertainties described in the "Risk Factors" sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Story continues

Investor Contact: Stern Investor Relations, Inc. Stephanie Ascher, 212-362-1200 stephanie@sternir.com

Media Contact:Lissette Steele, 202-930-4762lsteele@vergescientific.com

UNUM THERAPEUTICS INC.CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited, $ in thousands, except share and per share amounts)

UNUM THERAPEUTICS INC.CONSOLIDATED SELECTED BALANCE SHEET DATA(unaudited, in thousands)

December 31, 2018

Original post:
Unum Therapeutics Reports Third Quarter 2019 Financial Results - Yahoo Finance

Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell…

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of switch maintenance, the use of medicines not included in initial induction therapy, in this setting. NINLARO is currently not approved for this specific use.

We are very encouraged by the results of the TOURMALINE-MM4 trial and continue our forward momentum in developing maintenance options for multiple myeloma patients. Importantly, this is the third positive Phase 3 readout from the TOURMALINE clinical trial program, said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. We remain committed to bringing this convenient and well-tolerated treatment option to patients.

The safety profile of NINLARO in the maintenance setting was consistent with previously reported results of single-agent NINLARO use, and there were no new safety signals identified in TOURMALINE-MM4.

Full data results will be submitted for presentation at an upcoming medical meeting.

About the TOURMALINE-MM4 Trial

TOURMALINE-MM4 is a randomized, placebo-controlled, double-blind Phase 3 study of 706 patients, designed to determine the effect of single-agent oral NINLAROTM (ixazomib) maintenance therapy on progression-free survival (PFS), compared to placebo, in adult patients newly diagnosed with multiple myeloma not treated with stem cell transplantation, who have completed 6-12 months of initial therapy and achieved a partial response or better. For additional information, please visit https://clinicaltrials.gov/ct2/show/NCT02312258.

About Multiple Myeloma

Multiple myeloma is a life-threatening rare blood cancer that arises from the plasma cells, a type of white blood cell that is made in the bone marrow. These plasma cells become abnormal, multiply and release a type of antibody known as a paraprotein, which causes symptoms of the disease, including bone pain, frequent or recurring infections and fatigue, a symptom of anemia. These malignant plasma cells have the potential to affect many bones in the body and can cause a number of serious health problems affecting the bones, immune system, kidneys and red blood cell count. The typical multiple myeloma disease course includes periods of symptomatic myeloma followed by periods of remission. Nearly 230,000 people around the world live with multiple myeloma, with approximately 114,000 new cases diagnosed globally each year.

About NINLAROTM (ixazomib) capsules

NINLARO (ixazomib) is an oral proteasome inhibitor which is being studied across the continuum of multiple myeloma treatment settings. NINLARO was first approved by the U.S. Food and Drug Administration (FDA) in November 2015 and is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is currently approved in more than 60 countries, including the United States, Japan and in the European Union, with more than 10 regulatory filings currently under review. It was the first oral proteasome inhibitor to enter Phase 3 clinical trials and to receive approval.

The comprehensive ixazomib clinical development program, TOURMALINE, includes several ongoing pivotal trials, which together are investigating major multiple myeloma patient populations:

In addition to the TOURMALINE program, ixazomib is being evaluated in multiple therapeutic combinations for various patient populations in investigator initiated studies globally.

NINLAROTM (ixazomib) capsules: Global Important Safety Information

SPECIAL WARNINGS AND PRECAUTIONSThrombocytopenia has been reported with NINLARO (28% vs. 14% in the NINLARO and placebo regimens, respectively) with platelet nadirs typically occurring between Days 14-21 of each 28-day cycle and recovery to baseline by the start of the next cycle. It did not result in an increase in hemorrhagic events or platelet transfusions. Monitor platelet counts at least monthly during treatment with NINLARO and consider more frequent monitoring during the first three cycles. Manage with dose modifications and platelet transfusions as per standard medical guidelines.

Gastrointestinal toxicities have been reported in the NINLARO and placebo regimens respectively, such as diarrhea (42% vs. 36%), constipation (34% vs. 25%), nausea (26% vs. 21%), and vomiting (22% vs. 11%), occasionally requiring use of antiemetic and anti-diarrheal medications, and supportive care.

Peripheral neuropathy was reported with NINLARO (28% vs. 21% in the NINLARO and placebo regimens, respectively). The most commonly reported reaction was peripheral sensory neuropathy (19% and 14% in the NINLARO and placebo regimens, respectively). Peripheral motor neuropathy was not commonly reported in either regimen (< 1%). Monitor patients for symptoms of peripheral neuropathy and adjust dosing as needed.

Peripheral edema was reported with NINLARO (25% vs. 18% in the NINLARO and placebo regimens, respectively). Evaluate patients for underlying causes and provide supportive care, as necessary. Adjust the dose of dexamethasone per its prescribing information or the dose of NINLARO for severe symptoms.

Cutaneous reactions occurred in 19% of patients in the NINLARO regimen compared to 11% of patients in the placebo regimen. The most common type of rash reported in both regimens was maculo-papular and macular rash. Manage rash with supportive care, dose modification or discontinuation.

Hepatotoxicity, drug-induced liver injury, hepatocellular injury, hepatic steatosis, and hepatitis cholestatic have been uncommonly reported with NINLARO. Monitor hepatic enzymes regularly and adjust dose for Grade 3 or 4 symptoms.

Pregnancy- NINLARO can cause fetal harm. Advise male and female patients of reproductive potential to use contraceptive measures during treatment and for an additional 90 days after the final dose of NINLARO. Women of childbearing potential should avoid becoming pregnant while taking NINLARO due to potential hazard to the fetus. Women using hormonal contraceptives should use an additional barrier method of contraception.

Lactation- It is not known whether NINLARO or its metabolites are excreted in human milk. There could be potential adverse events in nursing infants and therefore breastfeeding should be discontinued.

SPECIAL PATIENT POPULATIONSHepatic Impairment: Reduce the NINLARO starting dose to 3 mg in patients with moderate or severe hepatic impairment.

Renal Impairment: Reduce the NINLARO starting dose to 3 mg in patients with severe renal impairment or end-stage renal disease (ESRD) requiring dialysis. NINLARO is not dialyzable and, therefore, can be administered without regard to the timing of dialysis.

DRUG INTERACTIONSCo-administration of strong CYP3A inducers with NINLARO is not recommended.

ADVERSE REACTIONSThe most frequently reported adverse reactions ( 20%) in the NINLARO regimen, and greater than in the placebo regimen, were diarrhea (42% vs. 36%), constipation (34% vs. 25%), thrombocytopenia (28% vs. 14%), peripheral neuropathy (28% vs. 21%), nausea (26% vs. 21%), peripheral edema (25% vs. 18%), vomiting (22% vs. 11%), and back pain (21% vs. 16%). Serious adverse reactions reported in 2% of patients included thrombocytopenia (2%) and diarrhea (2%). For each adverse reaction, one or more of the three drugs was discontinued in 1% of patients in the NINLARO regimen.

For European Union Summary of Product Characteristics: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf For US Prescribing Information: https://www.ninlarohcp.com/pdf/prescribing-information.pdf For Canada Product Monograph: http://www.takedacanada.com/ninlaropm

About Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Important NoticeFor the purposes of this notice, press release means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (Takeda) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words we, us and our are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking StatementsThis press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takedas future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as targets, plans, believes, hopes, continues, expects, aims, intends, ensures, will, may, should, would, could anticipates, estimates, projects or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takedas estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takedas global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takedas operations and the timing of any such divestment(s), any of which may cause Takedas actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takedas results, performance, achievements, or financial position, see Item 3. Key InformationD. Risk Factors in Takedas most recent Annual Report on Form 20-F and Takedas other reports filed with the U.S. Securities and Exchange Commission, available on Takedas website at: https://www.takeda.com/investors/reports/sec-filings/ or at http://www.sec.gov. Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takedas future results.

Read this article:
Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell...

Army veteran to save woman with blood cancer through stem cell donation – Stoke-on-Trent Live

An army veteran hopes he can save a woman's life by donating his stem cells.

Jack Griffiths signed up to the Anthony Nolan register to be a donor when he joined the army in 2011.

Eight years later he received the call to say that he was a match for a woman with blood cancer, and he now has the chance to save her life when he has the procedure on November 21.

Now the 25-year-old, from Silverdale, wants to encourage other men to sign up to the register as they are currently underrepresented.

The dad-of-one said: "I signed up to the register when I joined the forces in 2011, it was something I'd always wanted to do, I asked a lot of questions and then said yes.

"Then around three months ago I received a phone call saying I was a positive match. It is quite rare that you become a match so I thought it was a hoax call because I couldn't remember signing up until they explained.

"I lost my nana to cancer and my grandad passed away from Alzheimer's last week so when I had the phone call I thought if I can help somebody then I want to do it.

"I've got a five-year-old girl and at that point you don't know who the match is for, it could have been for a girl my daughter's age.

"The Anthony Nolan charity have told me I'm donating to an adult woman, they've clearly explained everything and are very understanding. It's a small procedure, you have a course of injections for four days before the actual transplant day.

"On the day of the procedure you have a tube in one arm which drains every bit of blood out of your body and filters all of the white cells out of your blood.

"Then the tube in the other arm puts the blood back in, it takes around six hours. I've done my research and the worst thing that can happen from the procedure is that your spleen can rupture but other than that there's been 35,000 stem cell donations and there's never been a fatal.

"You can have the procedure in three hospitals London, Sheffield or Manchester. They put you up in a hotel, they pay for food, travel expenses and your day's wages if you've had to come out of work.

"Before the procedure you can sign a piece of paper to keep in touch with the person you have donated to and if the other person says they want to as well you can meet up after two years.

"I would like to stay in touch with her, it's going to be a life saving procedure if everything goes succesfully. I really hope the procedure will be succesful."

Jack says you can sign up to the register if you are aged between 16 and 30.

The Bet365 employee said: "Only two per cent of the UK are registered as donors and 40,000 people who have blood cancer are waiting for people who could be a match.

"I want more people to sign up to the register and knock the numbers down from 40,000 as best as possible and save more lives. You can sign up if you are aged between 16 and 30.

"Since I've signed up some of my friends have also signed up straight away."

Alice Hirst, Regional Register Development Manager at Anthony Nolan, said: "Its incredible that, by signing up to the Anthony Nolan register in 2011 Jack is giving a patient, somewhere in the world, in desperate need of a stem cell transplant a second chance of life in 2019.

"Its a unique act of altruism which shows that every person who joins the Anthony Nolan register has the potential to give hope to somebody with blood cancer or a blood disorder.

"Wed like to thank Jack and are calling on other young men aged 16-30 and in good general health to consider joining the Anthony Nolan register. More than 50 per cent of donors in the UK are young men, however they make up just 18 per cent of our register.

"Were encouraging people to find out more by visiting our website, anthonynolan.org/jack, and see how you can go on standby to save a life."

Our new FREE WhatsApp service for you!

StokeonTrentLive has launched a WhatsApp service dedicated to keeping you up to date with the news! Click here to join and follow the instructions on your phone. Your number won't be shared with anyone else in the group. If you want more information on signing up, or if this link doesnt work, click here.

Visit link:
Army veteran to save woman with blood cancer through stem cell donation - Stoke-on-Trent Live

Financial Contrast: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) – DFS Caller

BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (NASDAQ:LVGO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

0.1% of Livongo Health shares are owned by institutional investors. 17.9% of BioRestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for BioRestorative Therapies and Livongo Health, as reported by MarketBeat.

Livongo Health has a consensus target price of $44.30, indicating a potential upside of 71.17%. Given Livongo Healths higher probable upside, analysts plainly believe Livongo Health is more favorable than BioRestorative Therapies.

Profitability

This table compares BioRestorative Therapies and Livongo Healths net margins, return on equity and return on assets.

Valuation & Earnings

This table compares BioRestorative Therapies and Livongo Healths top-line revenue, earnings per share (EPS) and valuation.

BioRestorative Therapies has higher earnings, but lower revenue than Livongo Health.

Summary

Livongo Health beats BioRestorative Therapies on 7 of the 9 factors compared between the two stocks.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells for the treatment of disc/spine disease and metabolic disorders. The company's lead cell therapy candidate is the BRTX-100, which focuses on providing non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. It also develops the ThermoStem program, a pre-clinical program for the treatment of metabolic diseases, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. In addition, the company provides curved needle device, a needle system with a curved inner cannula that allows access to difficult-to-locate regions for the delivery or removal of fluids and other substances. Further, it offers skin care products under the Stem Pearls brand name. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is headquartered in Melville, New York.

Livongo Health Company Profile

Livongo Health, Inc. provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications. Its products include Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength. The company was formerly known as EosHealth, Inc. and changed its name to Livongo Health, Inc. in 2014. Livongo Health, Inc. was incorporated in 2008 and is headquartered in Mountain View, California.

Original post:
Financial Contrast: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller

ISSCA Faculty Honored with Health Sciences Awards at Conference Held at the University of Miami – PRUnderground

Three faculty members with the International Society for Stem Cell Application (ISSCA) were honored with awards at the organizations recent regenerative medicine conference held at the University of Miami on October 24-27. The awards were sponsored by the Sociedad Internacional en Investigacin, Salud, Desarrollo Empresarial y Tecnologas (SISSDET) and lauded the honorees for their commitment to leadership and education in the field of regenerative medicine.

The three recipients of the awards are Dr. Damian Ariel Siano, Dra. Maritza Novas, and Dra. Silvina Pastrana. All three have continued to partner with the ISSCA and have notable contributions to the field by offering courses in regenerative medicine, helping thousands of doctors around the world add stem cells therapies to their medical practices.

Dr. Damian Ariel Siano is an orthopedic physician from Argentina who has dedicated his professional life to treat sports injuries. He is one of the most renowned sports medicine specialists in South America. Dr. Siano currently works with one of the most famous soccer teams in Argentina, using cell therapies to help professional athletes avoid unnecessary surgery and recuperate quicker from injuries.

Dra. Maritza Novas currently serves as the Director of Research and Development for the Global Stem Cells Group. For the past 10 years, she has dedicated herself to educating doctors in the latest stem cells advancements and conducting stem cell research. Dra. Novas has visited all continents, sharing her knowledge as a stem cells practitioner and researcher.

Dra. Silvina Pastrana is one of the first doctors that helped form the ISSCA. She has become a visionary in the field and is noted for creating her own stem cells protocols and using complementary therapies to get better results in patient who utilize cell therapies. Dra. Pastrana combines both ozone and vitamin C therapies before employing stem cell protocols, obtaining excellent results in treating patients with arthritis.

The ISSCA is committed to helping physicians who want to add regenerative medicine to their practices gain the education and tools to do that, said Benito Novas, Vice President of Public Relations for ISSCA. The three doctors recognized at our recent event at the University of Miami are prime examples of the high-quality instructors that physicians can anticipate working with when then attend one of our conferences. Congratulations to our faculty on receiving this prestigious award, and thank you to SISSDET for recognizing their accomplishments.

ISSCA is a global leader in stem cells research, applications, and education, partnering with major global institutions and locations worldwide to host its independent medical congresses. To learn more about the ISSCA and its all of its past and upcoming events, visit http://www.issca.us

About International Society for Stem Cells Applications

The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine. Their code of ethics emphasizes principles of morals and ethical conducts.

At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerativemedicine and make it available to benefit patients both nationally and globally.

For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com

Continued here:
ISSCA Faculty Honored with Health Sciences Awards at Conference Held at the University of Miami - PRUnderground

Learn How You Can Treat Your Pain with Regenerative Medicine! – Patch.com

Have you wondered about new and innovative pain treatment processes that could change your quality of life?

Join us Monday, December 16, 7PM at the Woodbridge Main Library as Manisha Chahal, MD of Edison-Metuchen Orthopaedic Group discusses Regenerative Medicine to Treat Pain. Dr. Chahal will walk us through the promising results of regenerative medicine with a focus on platelet rich plasma and stem cells. She will explain how this process works and the evidence to support this cutting edge science. Dr. Chahal will also describe the best practices to go about and the indications to look out for. She will disclose how to avoid misleading providers and illegitimate products.

About Dr. Manisha Chahal, MD

Dr. Manisha Chahal is a board certified Interventional Pain Management Physician who specializes in minimally invasive procedures for pain.

Dr. Chahal treats the following conditions: headache, lower back pain, joint pain, neck pain, CRPS, postherpetic neuralgia, abdominal wall pain, pelvic pain, coccydynia, and sciatica.

Additionally, Dr. Chahal also performs the following procedures: spinal cord stimulators, regenerative medicine (PRP & stem cell injections), Botox for migraines, cervical epidural steroid injection, lumbar translaminar or transforaminal epidural steroid injections, cervical and lumbar facet rhizotomy, discograms, nerve blocks (ultrasound & C-arm guided), knee genicular blocks & rhizotomy, joint injections, trigger point injections, and qutenza treatment (chemical rhizotomy) for PHN pain.

She received her medical degree from Howard University where she was awarded a Trustee Scholarship for academic achievement. She completed her anesthesia residency training at Beth Israel Deaconess Medical Center (Harvard) in Boston. Dr. Chahal did her Pain Management Fellowship at New York Presbyterian/ Weill Cornell Medical Center in NYC. She is board certified by the American Board of Anesthesiology for both anesthesia and pain medicine.

She treats a wide variety of pain diagnoses and has expertise in many procedures including spinal cord stimulators, transforaminal epidural injections, rhizotomies, ultrasound guided nerve blocks, regenerative treatments and botox.

Dr. Chahal's philosophy is use every pain management option available to help patients ease their pain and "get their life back."

The Woodbridge Main Library is located at 1 George Frederick Plaza in Woodbridge, NJ. If you have any questions or need any further information please contact us at 732-634-4450 or visit our website -www.woodbrigelibrary.org.

More:
Learn How You Can Treat Your Pain with Regenerative Medicine! - Patch.com

BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting – GlobeNewswire

NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Companys Chief Operating and Chief Medical Officer Ralph Kern MD MHSc will present at the 7th International Stem Cell Meeting, which is hosted by the Israel Stem Cell Society. The Conference will be held November 12-13, in Tel Aviv, Israel.

Ralph Kern, MD, MHSc, said: I welcome the opportunity to participate in the 7th International Stem Cell Meeting where I will share the advances BrainStorm has made with NurOwn. It is a privilege to participate and to exchange ideas with many of the international scientific leaders in stem cell research.

About NurOwn

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company's website at http://www.brainstorm-cell.com

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Original post:
BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting - GlobeNewswire

Notice of Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS – Business Wire

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Promethera Biosciences SA (Promethera) and MEDIPAL HOLDINGS CORPORATION (MEDIPAL) today announced that they have entered into a business alliance agreement. In conjunction with todays alliance, MEDIPAL has decided to increase its shareholdings in the Promethera Group. Details follows below.

The purpose of this alliancePromethera has been developing its lead liver cell-derived technology (HepaStem) in an area of high medical need, primarily for Non-alcoholic steatohepatitis (NASH), Acute-on-chronic liver failure (ACLF) and urea cycle disorder (UCD). Promethera completed the recruitment of 24 patients in its Phase 2a study in Acute-on-chronic liver failure (ACLF) in July 2019. The 3 months follow-up data were presented on 10th November at the AASLD 2019 conference (70th American Association for the Study of the Liver Diseases). In addition, the Phase 2a clinical study in patients with late stage NASH with worlds first cell therapy was initiated in May 2019. MEDIPAL will support Promethera in the commercialization of its products in Japan through the subscription to a private placement of new shares on March 20th, 2019, with the aim to expand the products it handles in the regenerative medicine field going forward.

The purpose of this alliance is to further deepen the cooperative relationship between the two companies by providing access to MEDIPALs know-how and capabilities in the distribution of cellular medicines at ultra-low temperatures. MEDIPAL will support Promethera's clinical trials and aims to provide a steady supply after its product launch.

With about 430 cases per year, the percent of patients receiving a liver transplant in Japan is significantly lower than in the US, where some 8,000 patients receive a transplant every year. Rescue solutions for Japanese patients with fatal liver diseases are performing poorly too. An even closer partnership with MEDIPAL will support us in setting up clinical trials in Japan that could positively impact and contribute to a solution for this considerable medical need in Japan. Building on this partnership, we will accelerate the clinical development of HepaStem towards a subsequent market launch in Japan, which will be a meaningful new development for Japanese patients suffering from end-stage liver disease, said Dr John Tchelingerian, President and CEO of Promethera. Mastering the entire supply chain is a key requirement for an off-the-shelf allogeneic cell therapy product, and MEDIPALs expertise and capabilities in this sector will be very valuable in this regard.

Prometheras HepaStem program can potentially become the worlds first therapeutic product using liver stem cells for the treatment of severe liver diseases, commented Shuichi Watanabe, Chief Executive Officer of MEDIPAL. Liver disease prevalence is rising in Japan and around the world due to an increase in obesity and other metabolic syndromes. The need to deliver effective treatments such as Prometheras is expected to augment rapidly. MEDIPALs system enables strict temperature management and traceability by using SDDU (Specialty Drug Distribution Unit: a liquid nitrogen-based ultra-low cold chain system for drug distribution) and has an extensive expertise in this field. We are very pleased with this partnership and the opportunity to support the development and the logistics of this innovative product candidate with our capabilities.

About MEDIPAL HOLDINGS CORPORATION

Head office

2-7-15, Yaesu Chuo-ku Tokyo 104-8461 Japan

Representative

Shuichi Watanabe, Representative Director, President and CEO

Business

As a holding company, MEDIPAL controls, administers and supports the operating activities of companies in which it holds shares in the Prescription Pharmaceutical Wholesale Business; the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business; and the Animal Health Products and Food Processing Raw Materials Wholesale Business, and conducts business development for the MEDIPAL Group.

Website

https://www.medipal.co.jp/english

About Promethera Biosciences S.A.

Head office

Watson & Crick Hill, Rue Granbonpr, 11 B-1435 Mont-Saint-Guibert, Belgium

Representative

John Tchelingerian, PhD, President & CEO

Business

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring patients life-saving treatments to reduce the need for liver transplantation. Promethera develops and manufactures allogeneic cell-based medicines for liver diseases by using regenerative medicine technology.

Website

https://www.promethera.com/

See the original post here:
Notice of Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS - Business Wire